Home / Generics / News / Mylan launches generic seizure drug in US

Mylan launches generic seizure drug in US Posted 12/02/2016

US generics manufacturer Mylan announced on 19 January 2016 that it had launched a generic version of Meda Pharms’ Felbatol (felbamate) tablets in dosages of 400 and 600 mg in the US.

The news comes after Mylan received US Food and Drug Administration (FDA) approval for its abbreviated new drug application (ANDA) on 11 January 2016.

Felbamate tablets are recommended for monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children.

According to IMS Health, felbamate tablets in dosages of 400 and 600 mg had US sales of approximately US$53 million for the 12 months ending 30 November 2015.

Other generics of Felbatol are already on the US market. Generic versions by Amneal Pharma and Corepharma were approved by FDA in September 2011 and November 2015, respectively.

Related article
Mylan launches generic asthma inhaler in UK 

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.

Source: Mylan, US FDA

Comments (0)

Generics News Research General

more

Biosimilars News Research General

more